Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation (AVRO)
This study is currently recruiting participants.
Verified by Cardiome Pharma, October 2009
First Received: April 25, 2008   Last Updated: October 13, 2009   History of Changes
Sponsor: Cardiome Pharma
Information provided by: Cardiome Pharma
ClinicalTrials.gov Identifier: NCT00668759
  Purpose

The primary objective of the study is to demonstrate the superiority of vernakalant injection over amiodarone injection in the conversion of atrial fibrillation (AF) to sinus rhythm (SR) within 90 minutes of the start of drug administration. The secondary objective is to compare the safety of vernakalant to amiodarone.


Condition Intervention Phase
Atrial Fibrillation
Drug: Vernakalant Injection
Drug: Amiodarone Injection:
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase III Prospective, Randomized, Double-Blind, Active-Controlled, Multi-Center, Superiority Study of Vernakalant Injection Versus Amiodarone in Subjects With Recent Onset Atrial Fibrillation

Resource links provided by NLM:


Further study details as provided by Cardiome Pharma:

Primary Outcome Measures:
  • Proportion of subjects with conversion of atrial fibrillation to sinus rhythm within 90 minutes after the start of infusion. [ Time Frame: Conversion of AF to SR for a minimum duration of one minute within 90 minutes after start of infusion. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to conversion within 90 minutes after the start of infusion. [ Time Frame: Time to conversion of AF to SR within 90 minutes after start of infusion. ] [ Designated as safety issue: No ]
  • Proportion of subjects with symptom relief at 90 minutes after the start of infusion. [ Time Frame: Relief of AF symptoms 90 minutes after start of infusion. ] [ Designated as safety issue: No ]
  • EQ-5D quality of life assessment. [ Time Frame: Assessment of quality of life 2 hours after start of infusion. ] [ Designated as safety issue: No ]
  • Monitoring of adverse events, vital signs, continuous telemetry monitoring, 12-lead Holter monitoring, 12-lead ECGs, and laboratory tests. [ Time Frame: Specified safety assessments completed at specified time points throughout the study from Screening to Discharge, at the Day 7 visit, and at the Day 30 follow-up call. ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 240
Study Start Date: April 2008
Estimated Study Completion Date: October 2009
Estimated Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental

Vernakalant Injection:

In one infusion line, subjects will receive a 10-minute infusion of vernakalant followed by a 15-minute observation period, followed by an additional 10-minute infusion of vernakalant if required (if the subject is still in AF). To maintain blinding, a 60-minute infusion of placebo (D5W) will be administered in a second infusion line, followed by a maintenance infusion of placebo for a minimum of an additional 60 minutes.

Drug: Vernakalant Injection
10-minute infusion of 3 mg/kg vernakalant injection followed by a 15-minute observation period, followed by an additional 10-minute infusion of 2 mg/kg of vernakalant if required (if the subject is still in AF).
2: Active Comparator

Amiodarone Injection:

In one infusion line subjects will receive a 60-minute infusion of amiodarone followed by a maintenance infusion of amiodarone over an additional 60 minutes. To maintain blinding, a 10-minute infusion of placebo (normal saline) will be administered in a second infusion line, followed by a 15 minute observation period, followed by a 10 minute infusion of placebo if the subject is still in AF.

Drug: Amiodarone Injection:
60-minute infusion of 5 mg/kg amiodarone followed by a maintenance infusion of 50 mg amiodarone over an additional 60 minutes (equivalent to approximately 15 mg/kg over 24 hrs).

Detailed Description:

This is a double-blind, active-controlled, double-dummy, multi-center, randomized trial in subjects with symptomatic AF of 3 to 48 hours duration.

Subjects will be randomized to receive vernakalant injection or amiodarone injection in a 1:1 ratio.

Safety will be assessed through the monitoring of adverse events, vital signs, continuous telemetry monitoring, 12-lead Holter monitoring, 12-lead ECGs, and laboratory tests.

At 2 hours after the start of infusion, electrical cardioversion may be performed or rate control medication may be administered. Class I and Class III antiarrhythmics are not to be administered for 24 hours after the start of infusion.

Subjects are to remain in the clinic for at least 6 hours after the start of infusion. Subjects will attend a follow-up visit at 7 (±2) days after treatment and will receive a follow-up telephone call at 30 (±3) days for assessment of serious adverse events, concomitant medications related to serious adverse events, and recurrence of AF.

All roles were blinded with the exception of each site's designated unblinded personnel who were responsible for randomization and preparation, dispensation and accountability of the study medication.

Expanded Access was not available through this protocol.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Have symptomatic AF of 3 to 48 hours duration at baseline.
  • Be eligible for cardioversion.
  • Have adequate anticoagulation therapy for cardioversion in accordance with standard of practice as recommended by ACC/AHA/ESC guidelines [1].
  • Be hemodynamically stable and have systolic blood pressure (BP) above 100 mmHg and less than 160 mmHg and diastolic BP less than 95 mmHg at screening and baseline.

Key Exclusion Criteria:

  • Known or suspected prolonged QT or uncorrected QT interval of >440 msec as measured at screening on a 12 lead ECG, familial long QT syndrome, or previous torsades de pointes, ventricular fibrillation; or sustained ventricular tachycardia (VT).
  • Symptomatic bradycardia, sick sinus syndrome, or ventricular rate less than 50 beats per minute (bpm) as documented by 12-lead ECG at screening.
  • A QRS interval >140 msec.
  • Atrial flutter.
  • Significant valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis.
  • Documented previous episodes of second or third degree atrioventricular (AV) block.
  • Had a myocardial infarction (MI), acute coronary syndrome or cardiac surgery within 30 days prior to entry into the study.
  • Uncorrected electrolyte imbalance of serum potassium or magnesium. Both K+ and Mg2+ must be corrected prior to dosing.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00668759

Contacts
Contact: Heather Kato, MAppSc 604-677-6905 ext 135 hkato@cardiome.com
Contact: Paul Holzapfel, RN, BSN 604-677-6905 ext 320 pholzapfel@cardiome.com

  Hide Study Locations
Locations
Australia, South Australia
Royal Adelaide Hospital Recruiting
Adelaide, South Australia, Australia, 5000
Contact: Ashley Roach     61 08 82222889     ashley.roach@health.sa.gov.au    
Principal Investigator: Julie Bradley, MD            
Australia, Tasmania
Royal Hobart Hospital Cardiology Research Recruiting
Hobart, Tasmania, Australia, 7000
Contact: Cathy McIntosh     61 3 6222 8287     cathy.mcintosh@dhhs.tas.gov.au    
Principal Investigator: Phil Roberts-Thomson, MD            
Launceston General Hospital Cardiac Research Unit Recruiting
Launceston, Tasmania, Australia
Contact: Gail McBain     61 3 63487583     gail.mcbain@dhhs.tas.gov.au    
Principal Investigator: Bhuwan Singh, MD            
Australia, Western Australia
Royal Perth Hospital Emergency Research Recruiting
Perth, Western Australia, Australia, 6000
Contact: Ellen MacDonald     61 8 9224 1724     ellen.macdonald@heath.wa.gov.au    
Principal Investigator: Simon Brown, MD            
Canada, Ontario
Kingston General Hospital Recruiting
Kingston, Ontario, Canada, K7L 2V7
Contact: Kathryn Bowes     613 549 6666 ext 2738     Bowesk@kgh.kari.net    
Principal Investigator: Marco Sivilotti, MD            
The Ottawa Hospital Recruiting
Ottawa, Ontario, Canada, K1Y 4E9
Contact: Cathy Clement, RN     613 798 5555 ext 16615     cclement@ohri.ca    
Principal Investigator: Ian Stiell, MD            
Canada, Quebec
Hopital de la Cite-de-la-Sante Recruiting
Laval, Quebec, Canada, H7M 3L9
Contact: Eric Daviau     450-668-1010 ext 2132     recherché.cardiologie.csssl@ssss.gouv.qc.ca    
Principal Investigator: Mayrand Helene, MD            
Institut de Cardiologie de Montreal Recruiting
Montreal, Quebec, Canada, H1T 1C8
Contact: Constance Bossy, RN     514 376 3330 ext 2884     Constance.Bossy@icm-mhi.org    
Principal Investigator: Denis Roy, MD            
Centre Hopitalier de L'Universite de Montreal - Hotel Dieu Recruiting
Montreal, Quebec, Canada, H2W 1T8
Contact: Carole Lemay, RN     514 890 8000 ext 14803     recherche.cardio.hd.chum@ssss.gouv.gc.ca    
Principal Investigator: Paolo Costi, MD            
McGill University Health Center The Montreal General Hospital Recruiting
Montreal, Quebec, Canada, H3G 1A4
Contact: Caroline Boudreault     514 934 1934 ext 43038     caroline.boudreault@muhc.mcgill.ca    
Principal Investigator: Thao Huynh, MD            
Centre de santé et de services sociaux du Sud de Lanaudière - Hôpital Pierre-Le Gardeur Recruiting
Terrebonne, Quebec, Canada, J6V 2H2
Contact: Margaux David, RN     450 654 7525 ext 11104     chlg.rech.cardio@ssss.gouv.qc.ca    
Principal Investigator: Denis-Carl Phaneuf, MD            
Czech Republic
Mestrska nemocnice Caslav Recruiting
Caslav, Czech Republic, 286 01
Contact: Hana Grunfeldova, MD     420 327 305 152     grunfeldova@email.cz    
Principal Investigator: Hana Grunfeldova, MD            
Nemocnice Kroměříž Terminated
Kroměříž, Czech Republic, 767 55
Nemocnice Kutna Hora s.r.o. Interni Oddeleni Terminated
Kutna Hora, Czech Republic
Nemocnice Decin Internal Medicine Recruiting
Nove Město, Czech Republic, 405 02
Contact: Michal Hondl, MD     420 737 889 772     michal.hondl@nemdc.cz    
Principal Investigator: Michal Hondl, MD            
VFN - III. Interni Klinika Recruiting
Praha, Czech Republic
Contact: Tomas Janota, MD     420-224-962-934        
Principal Investigator: Tomas Janota, MD            
Oblastni nemocnice Pribram Interni Oddeleni Terminated
Pribram, Czech Republic
Fakultní nemocnice v Motole, KAR Terminated
Praha, Czech Republic, 150 00
Ustredni vojenska nemocnice Koronarni jednotka Terminated
Praha, Czech Republic, 162 00
Nemocnice v Semilech Interní oddělení Recruiting
Semily, Czech Republic
Contact: Pavel Sabl, MD     420-481-661-333        
Principal Investigator: Pavel Sabl, MD            
Nemocnice Slaný Interní oddělení Recruiting
Slaný, Czech Republic
Contact: Ondrej Cermak, MD     420-312-575-338        
Principal Investigator: Ondrej Cermak, MD            
Nemocnice Tabor Recruiting
Tabor, Czech Republic, 390 03
Contact: Jana Mikulova, MD     420 602 692 259     janamikulova@seznam.cz    
Principal Investigator: Jana Mikulova, MD            
Uherskohradistska nemocnice Recruiting
Uherské Hradiste, Czech Republic, 686 08
Contact: Stanislav Zemek, MD     420 724 631 007     zemeks@post.cz    
Principal Investigator: Stanislav Zemek, MD            
Denmark
Gentofte Amtssygehus Kardiologisk afdeling Recruiting
Hellerup, Denmark
Contact: Gitte von Jessen     45 35 31 27 71     gvj@heart.dk    
Principal Investigator: Christian Torp-Pedersen, MD            
Herlev Amtssygehus, Kardiologisk Terminated
Herlev, Denmark, 2730
Sygehus Vendsyssel Hjorring Recruiting
Hjorring, Denmark
Contact: Jens Petersen, MD     45 99 64 31 01        
Principal Investigator: Jens Petersen, MD            
Roskilde Amts Sygehus Køge Recruiting
Koge, Denmark
Contact: Lone Brinksby     45 47 32 25 56        
Principal Investigator: Kim Klarlund, MD            
Regionshospitalet Silkeborg Recruiting
Silkeborg, Denmark
Contact: Malene Mortensen     45 87 22 23 49     projektM1@sc.aaa.dk    
Principal Investigator: Lars Frost, MD            
Estonia
Viimsi Hospital, Heart Clinic Recruiting
Haabneeme, Estonia, 74001
Contact: Juri Kaik, MD     372 5 031931     Jyri.Kaik@mail.ee    
Principal Investigator: Juri Kaik, MD            
Pärnu Hospital Department of Cardiology Recruiting
Parnu, Estonia
Contact: Veiko Vahula, MD     372 44 73310        
Principal Investigator: Veiko Vahula, MD            
East Tallinn Central Hospital-Clinic of Cardiology Recruiting
Tallinn, Estonia
Contact: Anne Kork, MD     372 62 07056        
Principal Investigator: Anne Kork, MD            
Tartu University Hospital Heart Clinic Active, not recruiting
Tartu, Estonia
Finland
Oulu University Hospital - Dept of Internal Medicine Active, not recruiting
Oulu, Finland, 90014
France
Hopital Trousseau - Service de Cardiologie Recruiting
Chambray-les-Tours, France
Contact: Dominique Babuty, MD     33 0 247 47 46 50        
Principal Investigator: Dominique Babuty, MD            
CHU de Nancy - Hopital Brabois - Service de Cardiologie Recruiting
Nancy, France
Contact: Etienne Aliot, MD     33 3 83 15 32 96        
Principal Investigator: Etienne Aliot, MD            
Hôpital Lariboisiere Terminated
Paris, France
CHU de Strasbourg - Hopital Hautepierre - Service de Cardiologie Terminated
Strasbourg, France
Germany
Campus Virchow-Klinikum, Charite - Universitaetsmedizin Berlin Recruiting
Berlin, Germany
Contact: Wilhelm Haverkamp, MD     49 30 450 653366        
Principal Investigator: Wilhelm Haverkamp, MD            
Klinikum der Stadt Ludwigshafen am Rhein gGmbH Recruiting
Ludwigshafen, Germany, 67063
Contact: Petra Zaricor     49 621 503 4354     zaricorp@klilu.de    
Principal Investigator: Karlheinz Seidl, MD            
Herzzentrum Brandenburg in Bernau Innere Medizin Recruiting
Bernau, Germany, 16321
Contact: Christian Butter, MD     49 3 338 694 610     c.butter@immanuel.de    
Principal Investigator: Christian Butter, MD            
Universitätsklinikum Bonn, Med. Klinik und Poliklinik II Terminated
Bonn, Germany, 53105
Johann Wolfgang Goethe Universitaet Med Klinik III - Kardiologie Recruiting
Frankfurt, Germany
Contact: Stefan Hohnloser, MD     49 69 6301 7404        
Principal Investigator: Stefan Hohnloser, MD            
Universitatsklinikum Gottingen, Herzzentrum Recruiting
Gottingen, Germany, 37075
Contact: Rolf Wachter, MD     49 551 398920        
Principal Investigator: Rolf Wachter, MD            
Martin-Luther Universitat Halle, Med. Klinik und Poliklinik III- Fachrichtung Kardiologie Recruiting
Halle, Germany
Contact: Michael Buerke, MD     49 221 4783 2401        
Principal Investigator: Michael Buerke, MD            
Klinik Hamburg Bambek Kardiologie Recruiting
Hamburg, Germany, 22291
Contact: Thora Botschafter     49 40 18 18 82 6317     t.botschafter@asklepios.com    
Principal Investigator: Gerian Grönefeld, MD            
Medizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer GmbH Recruiting
Hamburg, Germany, 22527
Contact: Dr. Tuebler, MD     49 40 889 009 899        
Contact: Frau Hoffmann     49 40 889 009 899     hoffmann@herz-hh.de    
Principal Investigator: Carsten Schwencke, MD            
Medizinische Klinik, Klinikum Hannover Nordstadt Recruiting
Hannover, Germany
Contact: Johannes Hensen, MD     49 511 9701291        
Principal Investigator: Johannes Hensen, MD            
Ambulantes Herzzentrum Kassel Innere Medizin Recruiting
Kassel, Germany, 34121
Contact: Ines Pietsch     49 (0)561 93769150        
Contact: Petra Becker     49 (0)561 93769150        
Principal Investigator: Andreas Utech, MD            
Klinikum der Universität Köln, Medizinische Klinik III Terminated
Köln, Germany, 50924
Charite Campus Mitte, Med. Klinik und Poliklinik mit Schwerpunkt Kardiologie und Angiologie Terminated
Berlin, Germany, 10117
Carl-von Basedow-Klinikum Merseburg Recruiting
Merseburg, Germany, 06217
Contact: Frau Dr. Susanne Rode, MD         S.Burghard@klinikum-saalekreis.de    
Principal Investigator: Roland Prondzinsky, MD            
Klinikum Pirna GmbH, Innere Medizin II, Kardiologie Recruiting
Pirna, Germany
Contact: Christoph Axthelm, MD     49 3501 7118 5041        
Principal Investigator: Christoph Axthelm, MD            
Krankenhaus Reinbek, St. Adolf-Stift Recruiting
Reinbek, Germany
Contact: Herbert Naegele, MD     49 40 72805158        
Principal Investigator: Herbert Naegele, MD            
Robert-Bosch-Krankenhaus, Abt. Kardiologie / Pulmologie Terminated
Stuttgart, Germany, 70376
Latvia
Latvian Center of Cardiology, P. Stradins Clinical University Hospital Recruiting
Riga, Latvia, LV1002
Contact: Iveta Mintale     371 67069959     iveta.mintale@stradini.lv    
Principal Investigator: Andrejs Erglis, MD            
Lithuania
Kaunas Medical University Hospital - Department of Cardiology Active, not recruiting
Kaunas, Lithuania
Klaipeda Seamen's Hospital Active, not recruiting
Klaipeda, Lithuania
Vilnius University Hospital Santariskiu Clinic - Center of Cardiology and Angiology Active, not recruiting
Vilnius, Lithuania
Netherlands
WCN - Department of Cardiology Rijnstate Ziekenhuls Recruiting
Arnhem, Netherlands, 6-800 TA
Contact: F F Willems, MD     31 88 005 7543     f.willem7@chello.nl    
Principal Investigator: F F Willems, MD            
Catharina Ziekenhuis Eindhoven Recruiting
Eindhoven, Netherlands, 5623EJ
Contact: Antoinette Spierings     31 40 2398362     carapl@cze.nl    
Principal Investigator: H R Michels, MD            
Groene Hart Zeikenhhaus Recruiting
Gouda, Netherlands, 2800BB
Contact: Marijke de Wit     31 18 250 5360     marijke.de.wit@ghz.nl    
Contact: Mrs. Kramer     31 18 250 5360     hanneke.kramer@ghz.nl    
Principal Investigator: Eric Viergever, MD            
WCN - Bethesda ziekenhuis Recruiting
Hoogeveen, Netherlands, 7909 AA
Contact: S H K The, MD     31 052 828 6222     shkthe@bethesda.nl    
Principal Investigator: S H K The, MD            
Academisch Ziekenhuis Maastricht Recruiting
Maastricht, Netherlands, 6229 HX
Contact: Iris Partouns-Hendricks     31 43 387 7091     iris.partouns.hendricks@mumc.nl    
Principal Investigator: An Moens, MD            
WCN - Canisius-Wilhelmina Ziekenhuis Recruiting
Nijmegen, Netherlands, 6532 SZ
Contact: Astrid Schut     31 24 365 8789     Res.car@cwz.nl    
Principal Investigator: D P Hertzberger, MD            
WCN - St. Franciscus Gasthuis Recruiting
Rotterdam, Netherlands, 3045 PM
Contact: Irene Kort     31 10 461 6790     i.kort@sfg.nl    
Contact: Ingrid Danse     31 10 461 6790     i.danse@sfg.nl    
Principal Investigator: P R Nierop, MD            
Poland
Oddzial Kardiologiczny Wielospecjalityczny Szpital Miejski im. Recruiting
Bydgoszcz, Poland
Contact: Andrzej Hoffmann, MD     48 52 3709300        
Principal Investigator: Andrzej Hoffmann, MD            
Szpital Miejski im. J. Brudzinskiego Oddzial Kardiologii Recruiting
Gdynia, Poland
Contact: Pawel Miekus, MD     48 58 6665580        
Principal Investigator: Pawel Miekus, MD            
Klinika Chorob Wewnetrznych z Oddzialem Farmakologii Klinicznej i Terapii Monitorowanej Recruiting
Lodz, Poland
Contact: Marlena Broncel, MD     48 42 2516002        
Principal Investigator: Marlena Broncel, MD            
Okregowy Szpital Kolejowy w Lublinie Samodzielny Active, not recruiting
Lublin, Poland
III Klinika Chorob Wewnetrznych i Kardiologii Recruiting
Warszawa, Poland, 00-382
Contact: Krzysztof Makowiecki, MD     48 22 6252231        
Principal Investigator: Krzysztof Makowiecki, MD            
Oddzial Kardiologii Inwazyjnej Szpital Specjalistyczny im. E.Szczeklika w Tarnowie Terminated
Tarnow, Poland, 33-100
Oddział Kardiologiczno-Internistyczny Specjalistyczny Szpital Miejski im. Mikołaja Kopernika Recruiting
Toruń, Poland, 87-100
Contact: Bartłomiej Jończy, MD     48 56 610 02 50     bartjon@o2.pl    
Principal Investigator: Bartłomiej Jończy, MD            
Specjalistyczny Szpital Miejski im. Mikołaja Kopernika Recruiting
Toruń, Poland, 87-100
Contact: Lidia Pawlowicz, MD     48 56 610 02 45     lpawlowicz@ksiaznica.torun.pl    
Principal Investigator: Lidia Pawlowicz, MD            
Wojskowy Instytut Medyczny, CSK MON Recruiting
Warszawa, Poland, 00-909
Contact: Leszek Kubik, MD     48 22 6816585        
Principal Investigator: Leszek Kubik, MD            
Oddział Internistyczno-Kardiologiczny Samodzielny Publiczny Szpital Wojewódzki im. Jana Bożego w Lublinie Recruiting
Lublin, Poland, 20-089
Contact: Hanna Lewandowska, MD     48 81 740 26 75     hannals@o2.pl    
Principal Investigator: Hanna Lewandowska, MD            
Klinika Kardiologii Zachowawczej Centralny Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji w Warszawie Recruiting
Warszawa, Poland, 02-507
Contact: Marek Kochmański     48 22 508 16 70        
Principal Investigator: Marek Kochmański, MD            
Osrodek Chorob Serca, Klinika Kardiologii, 4 Wojskowy Szpital Kliniczny z Poliklinika Samodzielny Recruiting
Wroclaw, Poland
Contact: Piotr Ponikowski, MD     48 71 7660250        
Principal Investigator: Piotr Ponikowski, MD            
Serbia
"Dedinje" Cardiovascular Institute Recruiting
Belgrade, Serbia, 11040
Contact: Petar Otasevic     381 11 360 16 69     potasevic@yahoo.com    
Principal Investigator: Milorad Borzanovic, MD            
Clinical Center of Serbia, Institute of CV Diseases Recruiting
Belgrade, Serbia, 11000
Contact: Arsen Ristic     381 11 361 47 38        
Principal Investigator: Petar Seferovic, MD            
Institute of Treatment and Reahabilitation 'Niska Banja' Recruiting
Niska Banja, Serbia, 18205
Contact: Bojan Ilic     381 18 450 22 26     bojanil@eunet.rs    
Principal Investigator: Stevan Ilic, MD            
Clinical Center Zemun, Dept. of Cardiology Recruiting
Zemun, Serbia, 11080
Contact: Predrag Milicevic     +381 11 377 27 62     milicevicp@hotmail.com    
Principal Investigator: Putnikovic Biljana, MD            
Slovakia
Middle Slovak Institute of Cardiovascular Diseases (SUSCCH) Recruiting
Banska Bysterica, Slovakia, 97401
Contact: Gabriela Kaliska, MD     421 48 441 3059        
Principal Investigator: Gabriela Kaliska, MD            
Interna klinika FN Trnava, Fakultna nemocnica Trnava Recruiting
Trnava, Slovakia, 91701
Contact: Vladimir Macek, MD     421 33 593 8251        
Principal Investigator: Vladimir Macek, MD            
Slovensky ustav srdcovych a cevnych chorob Terminated
Bratislava, Slovakia, 83348
ICU, Hospital Lipt. Mikulas Recruiting
Liptovsky Mikulas, Slovakia, 03101
Contact: Peter - Kycina, MD            
Principal Investigator: Peter - Kycina, MD            
FN - I. interna klinika Terminated
Nitra, Slovakia, 950 01
Liva - Central Military Hospital Recruiting
Ruzomberok, Slovakia, 03401
Contact: Miroslav Urban, MD     421 44 438 2844        
Principal Investigator: Miroslav Urban, MD            
NsP Prievidza so sidlom v Bojniciah Terminated
Bojnice, Slovakia, 97201
Internal Dep. Hospital Žilina Terminated
Žilina, Slovakia, 012 07
Sweden
Universitetssjukhuset MAS Active, not recruiting
Malmo, Sweden
Universityetssjukhuset, Orebro Recruiting
Orebro, Sweden
Contact: Lena Swedberg     46 19 602 1000        
Principal Investigator: Espen Fensgrud, MD            
Akademiska Sjukhuset, Uppsala Recruiting
Uppsala, Sweden
Contact: Yvonne Björkman     46 18 6112738        
Principal Investigator: Per Blomstrom, MD            
Ukraine
Donetsk Regional Clinical Hospital Terminated
Donetsk, Ukraine
City Clinical Hospital #8 Terminated
Kharkiv, Ukraine
City Clinical Hospital #9 Dept of Arrhythmia Terminated
Odessa, Ukraine
City Clinical Hospital #1 Intensive Care Unit Terminated
Kiev, Ukraine
N.D. Strazhesko Institute of Cardiology Intensive Care Unit Terminated
Kiev, Ukraine
Lugansk First Clinical Multiprofile Hospital #1, Cardiology Terminated
Lugansk, Ukraine
Lviv Reg St Clinical Treat-and-Diagn Cardio. Centre Dept of Myocardial Infarction Terminated
Lviv, Ukraine
Kiev City Clinical Hospital No 5, Coronary Care Unit Terminated
Kiev, Ukraine
Sponsors and Collaborators
Cardiome Pharma
Investigators
Principal Investigator: Tomas Janota, MD VFN III. interní klinika
Principal Investigator: Christian Torp-Pedersen, MD Gentofte Amtssygehus - Kardiologisk afdeling
Principal Investigator: Rein Kolk, MD Tartu University Hospital Heart Clinic
Principal Investigator: Etienne Aliot, MD CHU de Nancy - Hopital Brabois, Service de Cardiologie
Principal Investigator: Stefan Hohnloser, MD Johann Wolfgang Goethe Universitaet Med Klinik III - Kardiologie
Principal Investigator: Heikki Huikuri, MD Oulu University Hospital - Dept of Internal Medicine
Principal Investigator: Piotr Ponikowski, MD Osrodek Chorob Serca, Klinika Kardiologii, IV Wojskowy Szpital Kliniczny z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej we Wroclawiu
Principal Investigator: Steen Juul-Moller, MD Universitetssjukhuset MAS
  More Information

No publications provided

Responsible Party: Cardiome Pharma Corp. ( Dr Charles Fisher, Chief Medical Officer )
Study ID Numbers: VERI-305-AMIO
Study First Received: April 25, 2008
Last Updated: October 13, 2009
ClinicalTrials.gov Identifier: NCT00668759     History of Changes
Health Authority: Canada: Health Canada;   Czech Republic: State Institute for Drug Control;   Denmark: Danish Medicines Agency;   Estonia: The State Agency of Medicine;   Finland: Finnish Medicines Agency;   France: Afssaps - French Health Products Safety Agency;   Germany: Federal Institute for Drugs and Medical Devices;   Lithuania: State Medicine Control Agency - Ministry of Health;   Poland: Ministry of Health;   Slovakia: State Institute for Drug Control;   Sweden: Medical Products Agency;   Ukraine: Ministry of Health

Keywords provided by Cardiome Pharma:
atrial fibrillation
atrial fib
AF

Additional relevant MeSH terms:
Vasodilator Agents
Heart Diseases
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Cardiovascular Agents
Amiodarone
Pharmacologic Actions
Pathologic Processes
Therapeutic Uses
Cardiovascular Diseases
Atrial Fibrillation
Anti-Arrhythmia Agents
Arrhythmias, Cardiac

ClinicalTrials.gov processed this record on November 27, 2009